Owing to the complexities associated with the production of biologics, biopharmaceutical developers are likely to continue relying on contract service providers for various aspects of their respective product development programs
Roots Analysis has announced the addition of the “Biopharmaceutical Contract Biomanufacturing Market, (4th Edition), 2020-2030” report to its list of offerings.
Given the rising popularity of biologics and the 8,000+ such product candidates under clinical investigation, the opportunity for contract manufacturing service providers engaged in this domain, is high and anticipated to persist in the mid-long term, as well. In fact, since 2000, over 120 new CMOs have been established, offering a variety of cost-efficient manufacturing services and solutions to biologic developers.
To order this 780+ page report, which features 300+ figures and 270+ tables, please visit this – https://www.rootsanalysis.com/reports/view_document/biopharmaceutical-contract-manufacturing-market/250.html
Key Market Insights
Presently, 225 CMOs, possessing over 380 manufacturing facilities, claim to offer manufacturing services for biopharmaceutical products
The manufacturing services market for biopharmaceuticals is highly fragmented, featuring a mix of small, mid-sized, large and very large players. It is worth mentioning that more than 60% of CMOs mentioned in the report, have the necessary capabilities to manufacture biologics across all scales of operation.
More than 65% of service providers offer manufacturing services for recombinant proteins and peptides
Close to 58% of CMOs claim to have the required capabilities to offer antibody manufacturing services. It is worth mentioning that a number of biologics manufacturers are presently offering services related to the niche and emerging classes of biologics.